Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference

Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and CEO of Beyond Air, will be presenting a corporate overview and participating in 1×1 meetings at the Piper 34^th Annual Healthcare Conference being held November 29 – December 1, 2022 in New York, NY.